Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.
![]()
Reuters NewMedia - Tuesday November 14, 2000
Christopher Noble
Mogae said he was disappointed by the lack of response and accused the U.S. government of making "sympathetic noises" but doing little while African nations reeled on the edge of economic and demographic implosion.
Some 24 million people in Africa have HIV, the virus that causes AIDS, and millions have died. Infection levels are far higher there than the rest of the world. In Botswana, 36 percent of the adult population is HIV-positive, the highest rate in the world.
The epidemic has crushed the country, leaving it little hope of a speedy recovery. Mogae said life expectancy had fallen by at least 20 years to 47 years and that as many as half the natural deaths occurring in Botswana are HIV related.
Advanced medicines that have significantly prolonged the survival of U.S. and European AIDS sufferers are so expensive that most Africans have no hope of ever getting access to them, Mogae told a news conference at the end of an AIDS conference sponsored by the Harvard AIDS Institute.
Mogae said the inadequate response was particularly frustrating when looked at in context of the West's growing wealth.
"Your wealth in recent years increased by trillions and therefore what we owe is peanuts," Mogae told Reuters after a news conference, referring to Africa's debt.
"It will not affect anybody, not the balance sheets of banks or anybody. It's just a matter of principle. You are insisting on repayment as a matter of principle, but it has no financial consequences for anybody else except the debtor. For him it's a lot of money," he said.
There has been some improvement recently, Mogae said, though offers of loans and drug discounts were still insufficient.
"Pharmaceutical companies have come forward and offered us discounts. Some of these discounts are very generous but (the drugs) are still more than our faint means can allow us to afford and therefore we are still not able to take full advantage of the offer,' Mogae said.
Five major drug companies are negotiating discounts with African countries for some of the leading antiretroviral medications. In October, Glaxo Wellcome (quote from Yahoo! UK & Ireland: GLXO.L) reached a deal with Senegal to sell its leading anti AIDS drugs there for about $2 a day.
But in a region where much of the population lives on less than a dollar a day, even that price looks high, Mogae said.
The United Nations estimates that it will cost at least $3 billion a year to fight the epidemic in Africa, a figure that does not include the cost of anti-AIDS drugs.
"If you are dealing with these orders of magnitude, the offers by the pharmaceutical companies may in themselves be generous but still not affordable and that is why I am saying ... they should do more," Mogae said.
Mogae said African countries were prepared to play a role in the financing of HIV treatments, but that they could not do it alone.
"We are saying the rest of the world, including and especially the United States and the rest of the G7, at the governmental level should do something to make it possible for us to access these treatments that are currently available," Mogae said.
Mogae also urged drug companies to allow other countries to make cheaper, generic versions of their drugs.
001114
RE001114
Copyright © 2000 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Contact Reuters.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .